![]() |
||||
|
|
||||
|
|
||||
Re: ductal carcinoma in situ and hormone therapy replacementFrom: Robert Radnich, MD (anonymous@obgyn.net)Thu, 14 May 1998 05:52:08 -0500 (CDT)
Betty, Good question. You didn't give your age, but I assume you are postmenopausal since you are already on HRT. There seems to be a relationship between estrogens and breast CA. The most recent studies link this to the dose and time of exposure. I have some women who understand this and desire to continue HRT, but it is a risk. I would not advise you to continue HRT. Evista is a selective estrogen receptor modulator. It is claimed to prevent bone loss and to help prevent heart disease without stimulating the breast or uterus. Studies suggest that there is a protective effect on the breast - similar to tamoxephene. The studies have not been ongoing for long enough to really have adequate data, but it looks promising at this time. It is a new drug, and thus has some risk - yet undefined. It also does not help with the symptoms of menopause. All that being said, I would not discourage you from taking Evista. I think it would provide significant protection for your bones and heart - and probably also give you some protection to prevent a recurrance of the breast CA. I wish you well
At Wed, 13 May 1998, Betty wrote:
>
|
|
Return to ![]()
Report TECHNICAL Problems ONLY to: webmaster@obgyn.net
Last Updated: Mon Nov 2 07:13:17 2009
Women's Insurance Checklist from Auto Insurance Quote
home | medical professionals | women | industry | forums | international